A listing on Nasdaq Stockholm Main Market is a natural next step in the company’s development, it states.
“A move to Nasdaq Stockholm’s main market can contribute to increased interest from a broader investor base while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally,” says Monica Wallter, CEO, LIDDS.
“We now have larger and longer-term institutional and private investors”
LIDDS is in a strong growth and expansion phase with several key projects in clinical and preclinical phases, including Phase III Liproca Depot out-licensing, the Phase I NanoZolid-docetaxel study and an extensive preclinical program in immuno-oncology, it states.
“It is clear that our shareholder base has developed significantly in recent years, both in terms of number of shareholders and that we now have larger and longer-term institutional and private investors,” says Jan Törnell, Chairman of the Board of LIDDS.
A transition from Nasdaq First North to Nasdaq Stockholm’s Main Market has the potential to increase LIDDS visibility both locally and internationally, it states.
Photo of Monica Wallter: LIDDS